Tirzepatide + Retatrutide + AOD-9604 Metabolic Research Stack

Between 2021 and 2026, obesity pharmacology moved faster than in any prior decade. The progression from single GLP-1 receptor agonists (semaglutide) to dual GIP/GLP-1 agonists (Tirzepatide, licensed in the UK as Mounjaro for type 2 diabetes and obesity) to triple GIP/GLP-1/glucagon receptor agonists (Retatrutide, currently in Phase III) has produced successively larger mean body-weight reductions in each generation of clinical trials. Ania Jastreboff of Yale School of Medicine led the pivotal SURMOUNT-1 trial for Tirzepatide (NEJM, 2022) and the landmark Retatrutide Phase II publication (NEJM, 2023) — a rare distinction that places her at the centre of the field's two most-cited studies. This three-compound research stack positions those two incretin agonists as sequential protocols, with AOD-9604 — a 16-amino-acid C-terminal GH fragment with direct adipocyte lipolytic activity — running concurrently throughout. The result is a 12-week framework that addresses hypothalamic appetite regulation, pancreatic hormone balance, glucagon-mediated energy expenditure, and peripheral fat-cell catabolism through mechanistically distinct, non-overlapping pathways.

Why this 3-compound protocol? (Sequenced, not concurrent)

The critical design decision in this protocol is the word sequenced. No published human trial has studied simultaneous co-administration of Tirzepatide and Retatrutide. This is not an oversight: both drugs act at GIP and GLP-1 receptors, and the published GLP-1 agonist literature consistently uses one incretin agent at a time. Running them concurrently would compound GI adverse events (nausea, vomiting, delayed gastric emptying) with no additive mechanistic rationale at the receptor level — Retatrutide's incremental benefit over Tirzepatide comes from its additional glucagon receptor agonism, not from doubling GLP-1 receptor stimulation.

The sequencing design mirrors standard clinical-trial methodology. Weeks 1–6 use Tirzepatide titrated from 2.5 mg to 7.5 mg weekly, establishing GIP/GLP-1 dual agonism and allowing GI tolerance to develop on a well-characterised compound with an established UK regulatory approval. Weeks 7–12 transition to Retatrutide 2–6 mg weekly, adding glucagon receptor agonism on a substrate that has already adapted to incretin-class GI effects. AOD-9604 at 300 µg daily subcutaneous injection runs from week 1 through week 8, acting entirely independently of the incretin receptors through a β3-adrenoceptor-mediated lipolytic pathway in adipocytes — a mechanism that cannot interact pharmacodynamically with either GLP-1 or GIP receptor signalling.

Mechanism of action — each peptide

Summarised studies — the published research record

The published evidence base for the compounds in this protocol is among the strongest in peptide research, anchored by Phase II and Phase III randomised controlled trials with thousands of participants.

SURMOUNT-1 (Tirzepatide, 2022) — The pivotal trial (Jastreboff et al., NEJM; PMID 35658024) enrolled 2,539 participants with a BMI of 30 or greater and showed that 72 weeks of Tirzepatide 15 mg weekly produced a 20.9% mean body-weight reduction, with 89.5% of participants achieving at least 5% reduction and 56.8% achieving at least 20% reduction. Tirzepatide 5 mg produced 15.0% reduction, establishing a clear dose-response. The SURPASS programme (Frias et al., NEJM 2021; PMID 34170647; Rosenstock et al., Lancet 2021; PMID 34186022) subsequently documented HbA1c improvements of 1.8–2.1 percentage points across the dose range, underpinning the UK MHRA approval. SURMOUNT-3 (Wadden et al., Nature Medicine 2023; PMID 37491239) further demonstrated that initiating Tirzepatide after intensive lifestyle intervention produced an additional 18.4% weight reduction from the post-lifestyle baseline — suggesting the compound's appetite-suppression mechanism operates independently of prior caloric restriction status.

Retatrutide Phase II (2023) — The trial led by Jastreboff and colleagues (NEJM; PMID 37366315) produced results that fundamentally reset the ceiling for pharmacological weight loss. At 48 weeks, the 12 mg dose cohort achieved a 24.2% mean body-weight reduction, with a trajectory suggesting continued loss at 72 weeks. Importantly, the glucagon receptor agonism component was associated with a measurable increase in resting energy expenditure — a distinct mechanism from GLP-1-mediated satiety. Coskun et al.'s Cell Metabolism paper (2022; PMID 35508086) provided the translational mechanism: Retatrutide's glucagon agonism drives hepatic fatty-acid oxidation and increases adaptive thermogenesis in brown adipose tissue through a cAMP-dependent pathway, effects not achievable with GIP/GLP-1 dual agonism alone. The Phase III TRIUMPH programme is ongoing; no efficacy data from Phase III were available at the time of writing.

AOD-9604 metabolic data — Heffernan et al. (International Journal of Obesity 2001; PMID 11673762) reported that daily AOD-9604 injection in diet-induced obese mice produced a 50% greater reduction in fat mass compared to controls over 19 days, with no change in lean mass, no hyperglycaemia, and no IGF-1 elevation — a safety profile sharply different from full GH administration. Ng et al. (Hormone Research 2000; PMID 11146367) confirmed the β3-adrenoceptor mechanism in isolated adipocytes and provided the pharmacological basis for the fasted AM administration used in this protocol, as β3-adrenoceptor sensitivity is highest in the post-absorptive state.

Full research protocol

Weekly research timeline

• Tirzepatide phase (weeks 1–6): 4-week titration from 2.5 mg to 7.5 mg weekly with a 2-week consolidation at 7.5 mg. This mirrors the SURMOUNT-1 titration schedule. GI symptoms peak in weeks 1–3 and typically plateau by week 6 as gastric motility adapts.
• Transition week (end of week 6): A 48–72 hour washout of Tirzepatide injection timing before commencing Retatrutide is recommended in research protocols to avoid any additive acute GI burden. Tirzepatide's half-life of approximately 5 days means receptor occupancy is declining but not zero at transition.
• Retatrutide phase (weeks 7–12): Entry at 2 mg weekly — well below the Phase II starting dose of 1 mg in the most sensitive cohort — reflecting the residual GLP-1 receptor sensitisation from prior Tirzepatide exposure. Titration to 6 mg over four weeks, with 6 mg as the maximum research ceiling (below the Phase II 8 mg and 12 mg doses).
• AOD-9604 (weeks 1–8): Daily fasted subcutaneous injection throughout both incretin phases. No pharmacokinetic interaction with Tirzepatide or Retatrutide has been reported; the compounds do not share metabolic pathways or plasma protein binding sites.

Side-effect management in research protocols

The dominant adverse-event class for both Tirzepatide and Retatrutide is gastrointestinal: nausea, vomiting, constipation, diarrhoea and delayed gastric emptying. In SURMOUNT-1, GI events caused 4.3–7.1% of participants to discontinue Tirzepatide; the Retatrutide Phase II reported similar rates. Slow titration — the single most effective mitigation — is built into this protocol. Researchers should not escalate the dose if GI symptoms are not at baseline tolerability for at least 5 days of the preceding dose level. Constipation management with adequate hydration and fibre is important, as the delayed gastric emptying mechanism reduces gut transit speed independently of diet composition.

The boxed warning on incretin-class compounds relates to medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN-2). Rodent thyroid C-cell tumours were observed at doses far exceeding clinical exposure in GLP-1 receptor agonist carcinogenicity studies; the human relevance is uncertain but the regulatory class-effect warning applies equally to Tirzepatide and Retatrutide. Research protocols should exclude subjects with personal or family history of MTC or MEN-2. Baseline and periodic amylase/lipase monitoring is standard given the known association between incretin therapies and pancreatitis risk (absolute risk remains low but elevated versus background). Pre-existing gallbladder disease warrants additional monitoring: rapid weight loss accelerates gallstone formation, and all effective obesity agents share this indirect risk.

Reconstitution & storage notes

Tirzepatide research peptide reconstitutes in bacteriostatic water at 2 mg/mL; solutions are stable at 2–8°C for up to 28 days. Retatrutide is typically supplied lyophilised and reconstitutes cleanly at 1–2 mg/mL in bacteriostatic water; pH sensitivity is similar to other synthetic incretin peptides — avoid vortex mixing, which can cause aggregation. AOD-9604 reconstitutes readily at 1 mg/mL in bacteriostatic water; given the small volume of each 300 µg dose, a working concentration of 0.5 mg/mL (300 µg = 0.6 mL) reduces the need for precision micropipetting. All three peptides degrade with repeated freeze-thaw cycles; pre-aliquot into single-use volumes before any freeze storage intended to exceed 30 days.

Related research

Researchers investigating the GH fragment / lipolytic peptide axis alongside incretin therapy may also be interested in the Tesamorelin + AOD-9604 visceral fat stack, which pairs the GHRH analogue Tesamorelin — the only growth-hormone-axis peptide approved by the FDA for visceral adiposity reduction — with AOD-9604's direct lipolytic mechanism. For a mitochondria-targeted complementary approach, see the MOTS-c + AOD-9604 fat loss stack, which adds the mitochondrial-derived peptide MOTS-c to AOD-9604's adipocyte mechanism, targeting energy expenditure at the organelle level.